- Home
- CRL vs EXEL Comparison
CRL vs EXEL Comparison
Compare CRL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRL | EXEL |
|---|---|---|
| Founded | 1947 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.7B |
| IPO Year | 1999 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CRL | EXEL |
|---|---|---|
| Price | $353.71 | $64.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | ★ $314.20 | $55.53 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 1.60 |
| Revenue | ★ $1,857,601,000.00 | $452,477,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $2.53 | $13.62 |
| P/E Ratio | ★ N/A | $40.47 |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $146.20 | $36.00 |
| 52 Week High | $351.21 | $65.50 |
Technical Indicators
Market Signals| Indicator | CRL | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 72.76 |
| Support Level | $147.39 | $54.38 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 12.96 | 1.47 |
| MACD | 4.91 | 0.40 |
| Stochastic Oscillator | 95.56 | 91.17 |
Price Performance
Historical ComparisonAbout CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.